Clinical trial
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With…
NCT00136175 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00136175 |
|---|---|
| Title | Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder |
| Official title | Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel, Carboplatin, Gemcitabine |
| Enrollment | 68 |
| Start date | Nov 1, 1999 |
| Primary completion | Dec 1, 2005 |
| Completion | Oct 1, 2007 |
| First posted | Aug 26, 2005 |
| Last update posted | Jan 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: